Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-Reply

JAMA. 2023 Mar 28;329(12):1033-1034. doi: 10.1001/jama.2023.0496.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile*
  • Clostridium Infections* / microbiology
  • Clostridium Infections* / therapy
  • Follow-Up Studies
  • Gastrointestinal Microbiome* / drug effects
  • Probiotics* / pharmacology
  • Probiotics* / therapeutic use
  • Recurrence

Substances

  • Anti-Bacterial Agents